Literature DB >> 30680022

Ebselen protects rat hearts against myocardial ischemia-reperfusion injury.

Bin Cheng1, Jin-Peng Zhong2, Fu-Xia Wu2, Guan-Lan Li2, Qing-Xiao Ruan2, Gang Luo2, Hong Jiang1.   

Abstract

Ebselen is an organoselenium compound that has demonstrated potent antioxidant and anti-inflammatory effects in previous studies. The present study was conducted to evaluate the effect of ebselen on myocardial ischemia-reperfusion (I/R) injury in a rat model and to elucidate the related mechanisms. Myocardial infarct size was assessed using triphenyltetrazolium chloride staining. Myocardial injury was evaluated according to the histopathological and ultrastructural alterations of rat hearts and the serum activity levels of cardiac enzymes, including creatine kinase (CK), CK-MB isoenzyme and lactate dehydrogenase (LDH). Cardiomyocyte apoptosis was detected using the terminal dUTP nick end-labelling (TUNEL) assay. In addition, the expression of apoptosis-associated proteins was measured using western blot analysis. In heart tissue specimens the activity of superoxide dismutase (SOD) and glutathione peroxidase (GPx), and levels of malondialdehyde (MDA) and protein carbonyl (PC) were also detected. The results indicated that ebselen reduced I/R-induced increase in myocardial infarct size and prevented the I/R-induced decreases in ejection fraction and fractional shortening. Further of note, ebselen improved I/R-induced rat heart injury. This was indicated by attenuation of histological and ultrastructural changes; reduction of serum CK, CK-MB and LDH activity levels; and decreased cell apoptosis on TUNEL staining, which was verified by decreased expression of cleaved (C)-Caspase-8, C-Caspase-3, B-cell lymphoma 2 (Bcl-2)-associated X protein and C-PARP, and increased expression of Bcl-2. Additionally, SOD and GPx activity levels were significantly higher, while MDA and PC levels were significantly lower in the ebselen + I/R group compared with in the I/R group. In conclusion, the present results suggested that ebselen serves an important role in protecting against myocardial I/R injury. The underlying mechanism may involve suppression of cardiomyocyte apoptosis and promotion of antioxidant activity.

Entities:  

Keywords:  antioxidant; apoptosis; ebselen; ischemia-reperfusion; myocardial

Year:  2018        PMID: 30680022      PMCID: PMC6327602          DOI: 10.3892/etm.2018.7089

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  6 in total

1.  Modeling Secondary Iron Overload Cardiomyopathy with Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.

Authors:  June-Wha Rhee; Hyoju Yi; Dilip Thomas; Chi Keung Lam; Nadjet Belbachir; Lei Tian; Xulei Qin; Jessica Malisa; Edward Lau; David T Paik; Youngkyun Kim; Beatrice SeungHye Choi; Nazish Sayed; Karim Sallam; Ronglih Liao; Joseph C Wu
Journal:  Cell Rep       Date:  2020-07-14       Impact factor: 9.423

Review 2.  Modeling Nonischemic Genetic Cardiomyopathies Using Induced Pluripotent Stem Cells.

Authors:  Tarek Khedro; Jason M Duran; Eric D Adler
Journal:  Curr Cardiol Rep       Date:  2022-06-03       Impact factor: 3.955

Review 3.  The Potential Use of Ebselen in Treatment-Resistant Depression.

Authors:  Fitri Fareez Ramli; Philip J Cowen; Beata R Godlewska
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-16

4.  Blocking the A2B adenosine receptor alleviates myocardial damage by inhibiting spleen-derived MDSC mobilisation after acute myocardial infarction.

Authors:  Zongying Yu; Yang Ling; Qiancheng Xu; Yuhan Cao; Shengxing Tang; Cong Fu
Journal:  Ann Med       Date:  2022-12       Impact factor: 5.348

Review 5.  Toxicology and pharmacology of synthetic organoselenium compounds: an update.

Authors:  Cristina W Nogueira; Nilda V Barbosa; João B T Rocha
Journal:  Arch Toxicol       Date:  2021-04-01       Impact factor: 6.168

6.  Ebselen enhances insulin sensitivity and decreases oxidative stress by inhibiting SHIP2 and protects from inflammation in diabetic mice.

Authors:  Zydrune Polianskyte-Prause; Tuomas A Tolvanen; Sonja Lindfors; Kanta Kon; Laura C Hautala; Hong Wang; Tsutomu Wada; Hiroshi Tsuneki; Toshiyasu Sasaoka; Sanna Lehtonen
Journal:  Int J Biol Sci       Date:  2022-02-14       Impact factor: 6.580

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.